Skip to main content

LANCE Ultra Human PCSK9 Detection Kit, 10,000 Assay Points

The LANCE® Ultra Human PCSK9 Detection Kit is designed for detection and quantitation of human Proprotein Convertase Subtilisin/Kexin Type 9 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Part Number: TRF1270C
Unit Size: 500 Assay Points
Part Number: TRF1270M
Unit Size: 10,000 Assay Points
  • The LANCE Ultra Human PCSK9 Detection Kit is designed for detection and quantitation of human PCSK9 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

    • No-wash steps, no separation steps
    • TR-FRET technology
    • Sensitive detection
    • High reproducibility
    • Faster time-to-results
    • Easy automation
    • 96-well, 384-well, and 1536-well formats

    LANCE and LANCE (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.

    Human Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) belongs to the proteinase K subfamily of the secretory subtilase family. This glycoprotein contains 692 amino acids, including a signal peptide, a prodomain, and a catalytic domain. Initially synthesized as a soluble 74 kDa precursor protein, it is cleaved into 14 kDa and 60 kDa domains, which remain associated. This protein plays a major regulatory role in cholesterol homeostasis and is highly expressed in the kidney, liver, and intestine. PCSK9 binds to the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. Reduced LDLR levels result in decreased metabolism of low-density lipoprotein, which could lead to hypercholesterolemia. Inhibition of PCSK9 function is currently being explored as a means of lowering cholesterol levels. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia.

  • Application
    Protein Analysis & Detection
    Assay Points
    10000
    Assay Target Class
    Protein
    Automation Compatible
    Yes
    Brand
    LANCE Ultra
    Detection Method
    Time-Resolved Fluorescence (TRF)
    TR-FRET
    Experimental Type
    In vitro
    Quantity in a Package Amount
    1.0 Units
    Shipping Conditions
    Shipped in Blue Ice
    Therapeutic Area
    Metabolic
    Unit Size
    10,000 Assay Points